What is Alumis Inc.'s price / sales?

Alumis Inc. (ALMS) reported price / sales of 333.5× in Q1 2026.

What does price / sales mean?

Market capitalization at the quarter end divided by trailing-twelve-month revenue. The price the market pays for each dollar of sales.

Alumis Inc. ALMS Price / sales

Price / sales at other companies

Bristol-Myers SquibbBMY

2.6×-0.1×

AmgenAMGN

5.1×+0.2×

Celldex TherapeuticsCLDX

2,438.2×+2,279×

Dianthus TherapeuticsDNTH

509×+334×

Protagonist TherapeuticsPTGX

90.8×+76.5×

Kymera TherapeuticsKYMR

132.1×+102×

Other financials

Income statement

See full

Revenue$1.7M-90.0%

Operating income-$98.4M+3.1%

Net income-$93.1M+6.0%

EPS (diluted)-$0.74+59.3%

Balance sheet

See full

Cash & equivalents$63.9M-50.3%

Total debt$35.7M+1,881%

Total equity$567.0M+237%

Total assets$671.6M+157%

Cash flow

See full

Operating cash flow-$87.1M-8.4%

CapEx$164.0K+343%

Free cash flow-$87.2M-8.5%

Valuation

See full

Market cap$3.12B+739%

Enterprise value$3.1B+1,238%

Profitability

See full

Operating margin-5,364%—

Net margin-2,825.7%—

FCF margin-4,487.4%—

Returns & leverage

See full

Return on equity-64.6%—

Debt / equity0.1×+0.1×

Current ratio7.5×+3.8×

Where this comes from

Calculated from Alumis Inc.’s reported figures.

market cap/total revenue=333.5×

Based on the most recent quarter.

The official record: Alumis Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alumis Inc.'s price / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Alumis Inc.'s price / sales?: Alumis Inc. (ALMS) reported price / sales of 333.5× in Q1 2026.
What does price / sales mean?: Market capitalization at the quarter end divided by trailing-twelve-month revenue. The price the market pays for each dollar of sales.